Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients

Han-Yang LIANG; Dong LIU; Hao WANG; Zheng-Qing BA; Ying XIAO; Yi-Lu LIU; Yong WANG; Jian-Song YUAN

doi:10.26599/1671-5411.2023.10.002

Volume 20 Issue 10

Oct. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Geriatric Cardiology > 2023 > 20(10): 737-747

Please cite this article as: LIANG HY, LIU D, WANG H, BA ZQ, XIAO Y, LIU YL, WANG Y, YUAN JS. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients. J Geriatr Cardiol 2023; 20(10): 737−747. DOI: 10.26599/1671-5411.2023.10.002

Citation:

Please cite this article as: LIANG HY, LIU D, WANG H, BA ZQ, XIAO Y, LIU YL, WANG Y, YUAN JS. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients. J Geriatr Cardiol 2023; 20(10): 737−747. DOI: 10.26599/1671-5411.2023.10.002

Citation:

PDF( 977 KB)

Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients

doi: 10.26599/1671-5411.2023.10.002

Han-Yang LIANG^{1, *},
Dong LIU^{1, *},
Hao WANG¹,
Zheng-Qing BA¹,
Ying XIAO¹,
Yi-Lu LIU¹,
Yong WANG^{1, 2
,
,},
Jian-Song YUAN^{1, 2
,
,}

1.
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China
2.
Key Laboratory of Pulmonary Vascular Medicine, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China

^*The authors contributed equally to this manuscript

More Information

Corresponding author: tom4215403@163.com (WANG Y); jsyuantg@163.com (YUAN JS)
Available Online: 2023-10-26
Publish Date: 2023-10-30

Abstract

Abstract

BACKGROUND Both lung cancer and cardiometabolic diseases are leading causes of death in China, and they share some common risk factors. However, the prevalence and long-term effect of pre-existing cardiometabolic comorbidities (CMCs) on the survival of middle-aged and elderly lung cancer patients are still not clear. METHODS We consecutively recruited 3477 non-small cell lung cancer (NSCLC) patients between January 2011 and December 2018 from four cancer specialty hospitals in China. Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality. Hazard ratio (HR) for mortality and corresponding 95% CI were calculated. RESULTS The prevalence of CMCs was 30.0% in middle-aged NSCLC patients and 45.5% in elderly NSCLC patients. Log-rank analysis presented statistically significant differences in median survival time between patients with CMCs and without CMCs in both the middle-aged group (21.0 months vs. 32.0 months, P < 0.01) and the elderly group (13.0 months vs. 17.0 months, P = 0.01). Heart failure (HR = 1.754, 95% CI: 1.436–2.144, P < 0.001) and venous thrombus embolism (HR = 2.196, 95% CI: 1.691–2.853, P < 0.001) were independent risk factors for the survival of middle-aged NSCLC patients, while heart failure (HR = 1.709, 95% CI: 1.371–2.130, P < 0.001) continued to decrease overall survival in the elderly group. Hyperlipidemia may be a protective factor for survival in middle-aged group (HR = 0.741, 95% CI: 0.566–0.971, P = 0.030). CONCLUSIONS Our findings demonstrate for the first time the prevalence and prognostic value of pre-existing CMCs in Chinese middle-aged and elderly NSCLC patients.

FullText(HTML)

References(47)

References

[1]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115−132. doi: 10.3322/caac.21338
[2]	Shi JF, Wang L, Wu N, et al. Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer 2019; 128: 91−100. doi: 10.1016/j.lungcan.2018.11.031
[3]	Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004; 59: 602−607. doi: 10.1136/thx.2003.018044
[4]	Ambrogi V, Pompeo E, Elia S, et al. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur J Cardiothorac Su rg 2003; 23: 811−817. doi: 10.1016/S1010-7940(03)00093-9
[5]	Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lu ng Cancer 1998; 21: 105−113. doi: 10.1016/S0169-5002(98)00039-7
[6]	Takenaka T, Katsura M, Shikada Y, et al. The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer. Interact Cardiovasc Thorac Su rg 2013; 16: 270−274. doi: 10.1093/icvts/ivs489
[7]	Lüscher TF. Tumours and the heart: common risk factors, chemotherapy, and radiation. Eur Heart J 2016; 37: 2737−2738. doi: 10.1093/eurheartj/ehw451
[8]	Sase K, Fujisaka Y, Shoji M, et al. Cardiovascular complications associated with contemporary lung cancer treatments. Curr Treat Options Oncol 2021; 22: 71. doi: 10.1007/s11864-021-00869-6
[9]	Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019; 40: 3889−3897. doi: 10.1093/eurheartj/ehz766
[10]	Licker M, de Perrot M, Höhn L, et al. Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma. Eur J Cardioth orac Surg 1999; 15: 314−319. doi: 10.1016/S1010-7940(99)00006-8
[11]	Liu D, Ma Z, Yang J, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY) 2019; 11: 7948−7960. doi: 10.18632/aging.102301
[12]	Su C, Zhou F, Shen J, et al. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations: still a daily challenge. Eur J Cancer 2017; 83: 266−278. doi: 10.1016/j.ejca.2017.07.002
[13]	Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol 2013; 8: 1272−1281. doi: 10.1097/JTO.0b013e3182a007ba
[14]	Borghaei H, Yim YM, Guerin A, et al. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer 2018; 119: 112−119. doi: 10.1016/j.lungcan.2018.02.011
[15]	Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw 2021; 19: 254−266. doi: 10.6004/jnccn.2021.0013
[16]	Herrero Rivera D, Nieto-Guerrero Gómez JM, Cacicedo Fernández de Bobadilla J, et al. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment. Clin Transl Oncol 2019; 21: 1220−1230. doi: 10.1007/s12094-019-02047-5
[17]	Kravchenko J, Berry M, Arbeev K, et al. Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis. Lung Cancer 2015; 88: 85−93. doi: 10.1016/j.lungcan.2015.01.006
[18]	Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer 2003; 103: 792−802. doi: 10.1002/ijc.10882
[19]	Banke A, Schou M, Videbaek L, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail 2016; 18: 260−266. doi: 10.1002/ejhf.472
[20]	Kwak S, Kwon S, Lee SY, et al. Differential risk of incident cancer in patients with heart failure: a nationwide population-based cohort study. J Cardiol 2021; 77: 231−238. doi: 10.1016/j.jjcc.2020.07.026
[21]	Hasin T, Gerber Y, Weston SA, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. J Am Coll Cardiol 2016; 68: 265−271. doi: 10.1016/j.jacc.2016.04.053
[22]	Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271−289. doi: 10.3322/caac.21349
[23]	Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710−717. doi: 10.7326/0003-4819-91-5-710
[24]	Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869−2879. doi: 10.1002/cncr.11407
[25]	D’Souza M, Nielsen D, Svane IM, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 2021; 42: 1621−1631. doi: 10.1093/eurheartj/ehaa884
[26]	Anker MS, Coats AJS, Anker SD. Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail. Eur Heart J 2021; 42: 1637. doi: 10.1093/eurheartj/ehab063
[27]	Corrales-Rodriguez L, Blais N. Lung cancer associated venous thromboembolic disease: a comprehensive review. Lung Cancer 2012; 75: 1−8. doi: 10.1016/j.lungcan.2011.07.004
[28]	Su Y, Huo M, Hua L, et al. Association of venous thromboembolism and early mortality in patients with newly diagnosed metastatic non-small cell lung cancer. Cancer Ma nag Res 2021; 13: 4031−4040. doi: 10.2147/CMAR.S301088
[29]	Hill H, Robinson M, Lu L, et al. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thromb Res 2021; 208: 71−78. doi: 10.1016/j.thromres.2021.10.014
[30]	Lee YG, Kim I, Lee E, et al. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost 2014; 111: 1112−1120. doi: 10.1160/TH13-11-0956
[31]	Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008; 6: 601−608. doi: 10.1111/j.1538-7836.2008.02908.x
[32]	Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277−2285. doi: 10.1001/jama.2008.656
[33]	Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733−740. doi: 10.1016/S1470-2045(10)70151-0
[34]	Zhang Y, Xu J, Lou Y, et al. Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations. Int J Cancer 2017; 140: 1645−1652. doi: 10.1002/ijc.30581
[35]	Sok M, Ravnik J, Ravnik M. Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer. Wien Klin Wochen schr 2009; 121: 314−317. doi: 10.1007/s00508-009-1169-8
[36]	Li JR, Zhang Y, Zheng JL. Decreased pretreatment serum cholesterol level is related with poor prognosis in resectable non-small cell lung cancer. Int J Clin Exp Pathol 2015; 8: 11877−11883.
[37]	Chi PD, Liu W, Chen H, et al. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS One 2014; 9: e91080. doi: 10.1371/journal.pone.0091080
[38]	Lv Y, Miao LY, Chen QF, et al. Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma. Onco Targets Ther 2016; 9: 461−468. doi: 10.2147/OTT.S96199
[39]	Ma C, Wang X, Guo J, et al. Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study. Lipids Health Dis 2021; 20: 69. doi: 10.1186/s12944-021-01492-y
[40]	Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia. Nat Rev Dis Primers 2018; 4: 17105. doi: 10.1038/nrdp.2017.105
[41]	Irwin ME, Mueller KL, Bohin N, et al. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011; 226: 2316−2328. doi: 10.1002/jcp.22570
[42]	Hao B, Yu M, Sang C, et al. Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study. Lipids Health Dis 2018; 17: 278. doi: 10.1186/s12944-018-0925-z
[43]	Li R, Liu B, Liu Y, et al. Elevated serum lipid level can serve as early signal for metastasis for non-small cell lung cancer patients: a retrospective nested case-control study. J Cancer 2020; 11: 7023−7031. doi: 10.7150/jca.48322
[44]	YuPeng L, YuXue Z, PengFei L, et al. Cholesterol levels in blood and the risk of prostate cancer: a meta-analysis of 14 prospective studies. Cancer Epidemiol Biomarkers Prev 2015; 24: 1086−1093. doi: 10.1158/1055-9965.EPI-14-1329
[45]	Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. Br J Cancer 2021; 124: 663−670. doi: 10.1038/s41416-020-01143-6
[46]	Beeghly-Fadiel A, Khankari NK, Delahanty RJ, et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. Int J Epidemiol 2020; 49: 1117−1131. doi: 10.1093/ije/dyz242
[47]	Johnson KE, Siewert KM, Klarin D, et al. The relationship between circulating lipids and breast cancer risk: a Mendelian randomization study. PLoS Med 2020; 17: e1003302. doi: 10.1371/journal.pmed.1003302